MONDAY, Oct. 30, 2023 (HealthDay News) -- Americans have been getting COVID treatments such as Paxlovid for free, but that’s about to end.
The medications will enter the private market this week, the Associated Press reported.
The price for a five-day course of Paxlovid, made by Pfizer, will be $1,390.
Merck has not confirmed a price for its COVID treatment, Lagevrio, but told the AP that it will offer the treatment free to patients “who, without assistance, could not otherwise afford the product.”
The pills will still be available at no cost until those bought earlier by the federal government run out at pharmacies, hospitals and doctor’s offices, according to U.S. Health and Human Services officials. The government paid Pfizer $5 billion for 10 million courses of Paxlovid in 2021.
Once those are gone, those with private insurance may notice a co-pay charge, the AP reported.
People on Medicaid, Medicare or without medical insurance will not pay any out-of-pocket costs for these treatments through 2024, and Pfizer will offer co-pay assistance for Paxlovid through 2028.
The Department of Veterans Affairs, the Department of Defense and Indian Health Service will still have access to government stores of Paxlovid, the AP reported.
The federal government will also keep 1 million treatment courses in its stockpile.
“Pfizer is committed to a smooth commercial transition and is working collaboratively with the U.S. government and health care stakeholders to ensure broad and equitable access to this important medicine for all eligible patients,” the company told the AP.
Medical suppliers can begin ordering the treatment from the drug companies starting this week.
The U.S. Food and Drug Administration granted full approval to Paxlovid earlier this year. It’s meant for adults with COVID who have a high risk of hospitalization or death, including older adults and those with chronic conditions such as obesity, diabetes or asthma.
More information
The U.S. Centers for Disease Control and Prevention has more on COVID-19 treatments.
SOURCE: Associated Press
Robitussin Honey Cough Syrup Recalled Due to Fungal Threat
CVS Pulling Popular Cold Meds From Shelves After Report Deems Them to Be Useless
Antibiotics Probably Won't Ease Your Cough, Even If Infection is Bacterial: Study
Could Folks Suffer From 'Long Colds,' Similar to Long COVID?
As a Summer Surge of COVID Takes Hold, Don't Mistake It for a Cold
City Living Means More Coughs, Colds for Kids
Flu, COVID Cases Climb as RSV Infections Start to Level Off
Feed a Cold and a Fever, Experts Say
Majority of Workers at America's Nursing Homes Unvaccinated Against Flu, COVID
'Swine Flu' Strain Has Passed Between Humans & Pigs Hundreds of Times
Most U.S. Parents Plan to Vaccinate Kids Against Flu, RSV: Survey